Precision BioSciences Inc., a clinical stage gene editing company, has announced the results of Phase 1 safety and efficacy for Cohort 1 in the ELIMINATE-B trial, evaluating PBGENE-HBV for chronic hepatitis B. This first-in-human trial involves patients who are HBeAg-negative and treated with nucleos(t)ide analog therapies. Data from Cohort 1, administered at the lowest dose level of 0.2 mg/kg, has been collected as of the cutoff on July 28, 2025. Initial safety data from Cohort 2, dosed at 0.4 mg/kg, has also been released. Further clinical development will be supported by Mark Sulkowski, M.D. of Johns Hopkins University, who has expanded his advisory role to optimize trial strategies for PBGENE-HBV.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806619711) on August 06, 2025, and is solely responsible for the information contained therein.